BioSpace News Archive

Business

Big Pharma Layoffs by the Thousands: Are Bayer and BMS Harbingers of More?

Patent cliffs and other factors may lead other large drugmakers to embrace similar cost-cutting measures, experts tell BioSpace.

May 22, 2024
·
4 min read
·
Tyler Patchen
Deals

Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition

Days after backing out of two Ionis-partnered neuro programs, Biogen has inked a potential $1.8 billion buy of Human Immunology Biosciences and boosting its late-stage immunology pipeline.

May 22, 2024
·
2 min read
·
Tristan Manalac
Job Trends

5 Top Companies Hiring Research Associates

Looking for research associate jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you.

May 22, 2024
·
1 min read
·
Angela Gabriel
Drug Development

Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure

Otsuka Pharmaceuticals announced Wednesday it is ending development of drug candidate AVP-786 after failing to improve agitation associated with dementia due to Alzheimer’s disease.

May 22, 2024
·
1 min read
·
Kate Goodwin
Business

AstraZeneca Snags Option to Buy Versant’s New Obesity Biotech SixPeaks

SixPeaks Bio emerged from stealth Wednesday with up to $110 million, a deal with AstraZeneca and plans to take weight-loss candidates designed to preserve muscle mass toward the clinic.

May 22, 2024
·
2 min read
·
Nick Paul Taylor
Drug Development

BioSpace x DIA: Navigating the Emergence of CGT Combination Products

BioSpace’s Lori Ellis discusses the risks and challenges of cell and gene therapy combination products with DIA speakers James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.

May 22, 2024
·
1 min read
·
Lori Ellis